Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

Cytiva, a biopharma research and manufacturing specialist, rolled out a new cell therapy manufacturing platform the company developed as part of a collaboration with Gilead Sciences’ Kite Pharma unit.

Engineers have developed a novel method for manufacturing CAR T cells, one that takes just 24 hours and requires only one step, thanks to the use of lipid nanoparticles (LNPs), the potent delivery ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...